查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1652019

疫苗佐剂的全球市场:市场规模·占有率·趋势，产业分析 (各产品种类·各给药途径·疾病类别·各用途·各地区)，未来预测 (2025年～2034年)

Vaccine Adjuvants Market Size, Share, Trends, Industry Analysis Report: By Product Type, Route of Administration, Disease Type, Application, and Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 119 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的最新研究，全球疫苗佐剂市场规模预计到 2034 年将达到 6,035,040 亿美元。该报告对当前的市场动态提供了详细的见解，并对未来的市场成长进行了分析。

疫苗佐剂市场包括添加到疫苗中以增强免疫反应的物质。这些佐剂提高了疫苗的有效性，特别是针对难以治癒的疾病。疫苗需求的增加、佐剂技术的进步以及对疫苗接种意识的提高正在推动市场成长。各大公司正致力于开发安全性和有效性更高的新型佐剂。不断增长的疫苗接种计划和针对包括 COVID-19 在内的新兴疾病的疫苗需求正在推动市场的发展。

疫苗佐剂市场的成长是由对有效疫苗不断增长的需求推动的，特别是针对传染病和癌症免疫疗法。主要推动因素包括全球传染病发病率上升、对提高疫苗效力的需求日益增加以及政府和私营部门对疫苗研发的持续投资。疫苗佐剂市场的机会在于开发安全性较好的下一代佐剂，以及扩大佐剂在个人化医疗（包括癌症疫苗）的应用。市场趋势包括转向更先进的佐剂技术，例如基于脂质体和皂苷的佐剂，以及扩大疫苗研究以应对新出现的健康威胁。总体而言，在技术创新、策略合作伙伴关係和全球不断增长的医疗需求的支持下，市场有望稳步成长。

疫苗佐剂市场：概述

根据产品类型，明矾因其在疫苗中的长期使用和被证明的安全性而占据最大的市场占有率。然而，佐剂乳剂是成长最快的部分，这得益于传染病和疫情疫苗中增强的免疫反应。

根据给药途径，市场以肌肉注射途径为主，该途径广泛用于流感和 COVID-19 等各种传染病的疫苗。皮下给药显示出最高的增长，尤其是在治疗性疫苗和免疫疗法应用中。

根据疾病类型，由于针对流感、肝炎和 COVID-19 等疾病的疫苗接种计划正在进行中，传染病部门占据了疫苗佐剂市场收入占有率的主导地位。受免疫疗法疫苗和个人化医疗进步的推动，肿瘤学领域正在经历最快的成长。

根据应用，商业应用部门引领疫苗佐剂市场占有率，因为佐剂疫苗广泛应用于全球公共卫生活动。研究应用领域成长最快，这得益于疫苗开发和临床试验的投资不断增加，特别是癌症和治疗性疫苗。

北美凭藉其强大的医疗保健基础设施和大量的疫苗研究投资占据最大的市场占有率。由于医疗需求不断扩大、人口不断增长以及疫苗接种率不断提高，预计亚太地区将呈现最高成长。

目录

第1章 简介

第2章 摘要整理

第3章 分析方法

第4章 疫苗佐剂市场洞察

  • 市场概述
  • 疫苗佐剂的市场动态
    • 促进因素和机会
      • 日益重视先进的佐剂技术
      • 佐剂在流行病防范中的作用日益增强
      • 扩大个人化疫苗佐剂策略
    • 阻碍因素和课题
      • 监理课题
  • 大环境分析
  • 疫苗佐剂市场趋势
  • 价值链分析
  • COVID-19影响分析

第5章 全球疫苗佐剂市场:各产品种类

  • 主要调查结果
  • 简介
  • 微粒子佐剂
  • 佐剂乳胶
  • 病原体成分
  • 明矾
  • 其他

第6章 全球疫苗佐剂市场:各给药途径

  • 主要调查结果
  • 简介
  • 肌肉内给药
  • 皮下注射治疗
  • 其他

第7章 全球疫苗佐剂市场:疾病类别

  • 主要调查结果
  • 简介
  • 感染疾病
  • 癌症
  • 其他

第8章 全球疫苗佐剂市场:各用途

  • 主要调查结果
  • 简介
  • 研究用途
  • 商业用途

第9章 全球疫苗佐剂市场:各地区

  • 主要调查结果
  • 简介
    • 疫苗佐剂市场评估:各地区 (2020～2034年)
  • 北美
    • 北美:各产品种类 (2020～2034年)
    • 北美:各给药途径 (2020～2034年)
    • 北美:各用途 (2020～2034年)
    • 北美:疾病类别 (2020～2034年)
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲:各产品种类 (2020～2034年)
    • 欧洲:各给药途径 (2020～2034年)
    • 欧洲:各用途 (2020～2034年)
    • 欧洲:疾病类别 (2020～2034年)
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 荷兰
    • 俄罗斯
    • 其他欧洲
  • 亚太地区
    • 亚太地区:各产品种类 (2020～2034年)
    • 亚太地区:各给药途径 (2020～2034年)
    • 亚太地区:各用途 (2020～2034年)
    • 亚太地区:疾病类别 (2020～2034年)
    • 中国
    • 印度
    • 马来西亚
    • 日本
    • 印尼
    • 韩国
    • 澳洲
    • 其他亚太地区
  • 中东·非洲
    • 中东·非洲:各产品种类 (2020～2034年)
    • 中东·非洲:各给药途径 (2020～2034年)
    • 中东·非洲:各用途 (2020～2034年)
    • 中东·非洲:疾病类别 (2020～2034年)
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 南非
    • 其他中东·非洲
  • 南美
    • 南美:各产品种类 (2020～2034年)
    • 南美:各给药途径 (2020～2034年)
    • 南美:各用途 (2020～2034年)
    • 南美:疾病类别 (2020～2034年)
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他南美国家

第10章 竞争情形

  • 事业扩大·企业收购的分析
    • 事业扩大
    • 企业收购
  • 联盟/合作/协定/公开

第11章 企业简介

  • GlaxoSmithKline(GSK)
  • Novavax
  • Merck & Co.
  • Sanofi
  • CSL Limited
  • Adjuvance Technologies
  • SEPPIC
  • Croda International
  • Vaxine Pty Ltd
  • Brenntag Biosector
  • Vaccitech(University of Oxford spin-off)
  • Emergent BioSolutions
  • Avanti Polar Lipids
  • Daiichi Sankyo
  • ImmunoScience
Product Code: PM1684

The global vaccine adjuvants market size is expected to reach USD 6,035.04 million by 2034, according to a new study by Polaris Market Research. The report "Vaccine Adjuvants Market Size, Share, Trends, Industry Analysis Report: By Product Type (Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Alum, and Others), Route of Administration, Disease Type, Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The vaccine adjuvants market involves substances added to vaccines to enhance immune responses. These adjuvants improve the efficacy of vaccines, particularly for challenging diseases. Growing demand for vaccines, advancements in adjuvant technologies, and increased awareness of immunization are driving market growth. Key players focus on developing new adjuvants with improved safety and effectiveness. The market is fueled by rising vaccination programs and the need for vaccines against emerging diseases, including COVID-19.

The vaccine adjuvants market growth is driven by the increasing demand for effective vaccines, particularly for infectious diseases and cancer immunotherapy. Key drivers include the rising incidence of infectious diseases across the world, increasing need for enhanced vaccine efficacy, and continued government and private sector investments in vaccine development. Vaccine adjuvants market opportunities lie in the development of next-generation adjuvants with better safety profiles and the growing use of adjuvants in personalized medicine, including cancer vaccines. Market trends include a shift toward more advanced adjuvant technologies, such as liposome-based and saponin-based adjuvants, and the expansion of vaccine research in response to emerging health threats. Overall, the market is poised for steady growth, supported by innovation, strategic collaborations, and increasing healthcare needs worldwide.

Vaccine Adjuvants Market Report Highlights

Based on product type, the alum segment holds the largest market share due to its long-standing use in vaccines and proven safety. However, adjuvant emulsions are the fastest-growing segment, driven by their enhanced immune response in vaccines for infectious diseases and pandemics.

By route of administration, the intramuscular route segment dominates the market due to its widespread use in vaccines for various infectious diseases, such as influenza and COVID-19. The subcutaneous route is registering the highest growth, particularly in therapeutic vaccines and immunotherapy applications.

In terms of disease type, the infectious diseases segment dominates the vaccine adjuvants market revenue share, driven by ongoing vaccination programs for diseases such as influenza, hepatitis, and COVID-19. The cancer segment is experiencing the highest growth, fueled by advancements in immunotherapy vaccines and personalized medicine.

The commercial application segment, by application, leads the vaccine adjuvants market share owing to the widespread use of adjuvanted vaccines in public health initiatives globally. The research application segment is growing the fastest, supported by increased investments in vaccine development and clinical trials, especially in cancer and therapeutic vaccines.

North America holds the largest market share due to its strong healthcare infrastructure and substantial vaccine research investments. Asia Pacific is registering the highest growth, driven by expanding healthcare needs, large populations, and increasing vaccine adoption.

Polaris Market Research has segmented the vaccine adjuvants market report on the basis of product type, route of administration, disease type, application, and region:

By Product Type Outlook (Revenue - USD Million, 2020-2034)

  • Particulate Adjuvants
  • Adjuvant Emulsions
  • Pathogen Components
  • Alum
  • Others

By Route of Administration Outlook (Revenue - USD Million, 2020-2034)

  • Intramuscular Route
  • Subcutaneous Route
  • Others

By Disease Type Outlook (Revenue - USD Million, 2020-2034)

  • Infectious Diseases
  • Cancer
  • Others

By Application Outlook (Revenue - USD Million, 2020-2034)

  • Research Application
  • Commercial Application

By Regional Outlook (Revenue - USD Million, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Source
    • 3.2.1. Primary Source
    • 3.2.2. Secondary Source

4. Global Vaccine Adjuvants Market Insights

  • 4.1. Vaccine Adjuvants Market - Market Snapshot
  • 4.2. Vaccine Adjuvants Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Focus on Advanced Adjuvant Technologies
      • 4.2.1.2. Growing Role of Adjuvants in Pandemic Preparedness
      • 4.2.1.3. Expansion of Personalized Vaccine Adjuvant Strategies
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Regulatory Challenges
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Vaccine Adjuvants Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Vaccine Adjuvants Market, by Product Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • 5.3. Particulate Adjuvants
    • 5.3.1. Global Vaccine Adjuvants Market, by Particulate Adjuvants, by Region, 2020-2034 (USD Million)
  • 5.4. Adjuvant Emulsions
    • 5.4.1. Global Vaccine Adjuvants Market, by Adjuvant Emulsions, by Region, 2020-2034 (USD Million)
  • 5.5. Pathogen Components
    • 5.5.1. Global Vaccine Adjuvants Market, by Pathogen Components, by Region, 2020-2034 (USD Million)
  • 5.6. Alum
    • 5.6.1. Global Vaccine Adjuvants Market, by Alum, by Region, 2020-2034 (USD Million)
  • 5.7. Others
    • 5.7.1. Global Vaccine Adjuvants Market, by Others, by Region, 2020-2034 (USD Million)

6. Global Vaccine Adjuvants Market, by Route of Administration

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • 6.3. Intramuscular Route
    • 6.3.1. Global Vaccine Adjuvants Market, by Intramuscular Route, by Region, 2020-2034 (USD Million)
  • 6.4. Subcutaneous Route
    • 6.4.1. Global Vaccine Adjuvants Market, by Subcutaneous Route, by Region, 2020-2034 (USD Million)
  • 6.5. Others
    • 6.5.1. Global Vaccine Adjuvants Market, by Others, by Region, 2020-2034 (USD Million)

7. Global Vaccine Adjuvants Market, by Disease Type

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • 7.3. Infectious Diseases
    • 7.3.1. Global Vaccine Adjuvants Market, by Infectious Diseases, by Region, 2020-2034 (USD Million)
  • 7.4. Cancer
    • 7.4.1. Global Vaccine Adjuvants Market, by Cancer, by Region, 2020-2034 (USD Million)
  • 7.5. Others
    • 7.5.1. Global Vaccine Adjuvants Market, by Others, by Region, 2020-2034 (USD Million)

8. Global Vaccine Adjuvants Market, by Application

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • 8.3. Research Application
    • 8.3.1. Global Vaccine Adjuvants Market, by Research Application, by Region, 2020-2034 (USD Million)
  • 8.4. Commercial Application
    • 8.4.1. Global Vaccine Adjuvants Market, by Commercial Application, by Region, 2020-2034 (USD Million)

9. Global Vaccine Adjuvants Market, by Geography

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. Vaccine Adjuvants Market Assessment, By Geography, 2020-2034 (USD Million)
  • 9.3. Vaccine Adjuvants Market - North America
    • 9.3.1. North America: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
    • 9.3.2. North America: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
    • 9.3.3. North America: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
    • 9.3.4. North America: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.3.5. Vaccine Adjuvants Market - US
      • 9.3.5.1. US: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.3.5.2. US: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.3.5.3. US: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.3.5.4. US: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.3.6. Vaccine Adjuvants Market - Canada
      • 9.3.6.1. Canada: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.3.6.2. Canada: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.3.6.3. Canada: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.3.6.4. Canada: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • 9.4. Vaccine Adjuvants Market - Europe
    • 9.4.1. Europe: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
    • 9.4.2. Europe: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
    • 9.4.3. Europe: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
    • 9.4.4. Europe: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.4.5. Vaccine Adjuvants Market - UK
      • 9.4.5.1. UK: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.4.5.2. UK: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.4.5.3. UK: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.4.5.4. UK: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.4.6. Vaccine Adjuvants Market - France
      • 9.4.6.1. France: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.4.6.2. France: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.4.6.3. France: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.4.6.4. France: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.4.7. Vaccine Adjuvants Market - Germany
      • 9.4.7.1. Germany: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.4.7.2. Germany: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.4.7.3. Germany: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.4.7.4. Germany: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.4.8. Vaccine Adjuvants Market - Italy
      • 9.4.8.1. Italy: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.4.8.2. Italy: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.4.8.3. Italy: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.4.8.4. Italy: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.4.9. Vaccine Adjuvants Market - Spain
      • 9.4.9.1. Spain: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.4.9.2. Spain: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.4.9.3. Spain: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.4.9.4. Spain: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.4.10. Vaccine Adjuvants Market - Netherlands
      • 9.4.10.1. Netherlands: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.4.10.2. Netherlands: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.4.10.3. Netherlands: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.4.10.4. Netherlands: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.4.11. Vaccine Adjuvants Market - Russia
      • 9.4.11.1. Russia: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.4.11.2. Russia: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.4.11.3. Russia: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.4.11.4. Russia: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.4.12. Vaccine Adjuvants Market - Rest of Europe
      • 9.4.12.1. Rest of Europe: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.4.12.2. Rest of Europe: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.4.12.3. Rest of Europe: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.4.12.4. Rest of Europe: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • 9.5. Vaccine Adjuvants Market - Asia Pacific
    • 9.5.1. Asia Pacific: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
    • 9.5.2. Asia Pacific: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
    • 9.5.3. Asia Pacific: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
    • 9.5.4. Asia Pacific: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.5.5. Vaccine Adjuvants Market - China
      • 9.5.5.1. China: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.5.5.2. China: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.5.5.3. China: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.5.5.4. China: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.5.6. Vaccine Adjuvants Market - India
      • 9.5.6.1. India: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.5.6.2. India: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.5.6.3. India: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.5.6.4. India: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.5.7. Vaccine Adjuvants Market - Malaysia
      • 9.5.7.1. Malaysia: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.5.7.2. Malaysia: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.5.7.3. Malaysia: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.5.7.4. Malaysia: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.5.8. Vaccine Adjuvants Market - Japan
      • 9.5.8.1. Japan: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.5.8.2. Japan: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.5.8.3. Japan: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.5.8.4. Japan: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.5.9. Vaccine Adjuvants Market - Indonesia
      • 9.5.9.1. Indonesia: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.5.9.2. Indonesia: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.5.9.3. Indonesia: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.5.9.4. Indonesia: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.5.10. Vaccine Adjuvants Market - South Korea
      • 9.5.10.1. South Korea: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.5.10.2. South Korea: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.5.10.3. South Korea: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.5.10.4. South Korea: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.5.11. Vaccine Adjuvants Market - Australia
      • 9.5.11.1. Australia: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.5.11.2. Australia: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.5.11.3. Australia: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.5.11.4. Australia: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.5.12. Vaccine Adjuvants Market - Rest of Asia Pacific
      • 9.5.12.1. Rest of Asia Pacific: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.5.12.2. Rest of Asia Pacific: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.5.12.3. Rest of Asia Pacific: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.5.12.4. Rest of Asia Pacific: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • 9.6. Vaccine Adjuvants Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
    • 9.6.2. Middle East & Africa: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
    • 9.6.3. Middle East & Africa: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
    • 9.6.4. Middle East & Africa: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.6.5. Vaccine Adjuvants Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.6.5.2. Saudi Arabia: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.6.5.3. Saudi Arabia: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.6.5.4. Saudi Arabia: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.6.6. Vaccine Adjuvants Market - UAE
      • 9.6.6.1. UAE: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.6.6.2. UAE: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.6.6.3. UAE: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.6.6.4. UAE: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.6.7. Vaccine Adjuvants Market - Israel
      • 9.6.7.1. Israel: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.6.7.2. Israel: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.6.7.3. Israel: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.6.7.4. Israel: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.6.8. Vaccine Adjuvants Market - South Africa
      • 9.6.8.1. South Africa: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.6.8.2. South Africa: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.6.8.3. South Africa: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.6.8.4. South Africa: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.6.9. Vaccine Adjuvants Market - Rest of Middle East & Africa
      • 9.6.9.1. Rest of Middle East & Africa: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.6.9.2. Rest of Middle East & Africa: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.6.9.3. Rest of Middle East & Africa: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.6.9.4. Rest of Middle East & Africa: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • 9.7. Vaccine Adjuvants Market - Latin America
    • 9.7.1. Latin America: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
    • 9.7.2. Latin America: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
    • 9.7.3. Latin America: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
    • 9.7.4. Latin America: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.7.5. Vaccine Adjuvants Market - Mexico
      • 9.7.5.1. Mexico: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.7.5.2. Mexico: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.7.5.3. Mexico: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.7.5.4. Mexico: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.7.6. Vaccine Adjuvants Market - Brazil
      • 9.7.6.1. Brazil: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.7.6.2. Brazil: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.7.6.3. Brazil: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.7.6.4. Brazil: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.7.7. Vaccine Adjuvants Market - Argentina
      • 9.7.7.1. Argentina: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.7.7.2. Argentina: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.7.7.3. Argentina: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.7.7.4. Argentina: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
    • 9.7.8. Vaccine Adjuvants Market - Rest of Latin America
      • 9.7.8.1. Rest of Latin America: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
      • 9.7.8.2. Rest of Latin America: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
      • 9.7.8.3. Rest of Latin America: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
      • 9.7.8.4. Rest of Latin America: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. GlaxoSmithKline (GSK)
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Novavax
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Merck & Co.
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Sanofi
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. CSL Limited
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Adjuvance Technologies
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. SEPPIC
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Croda International
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Vaxine Pty Ltd
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Brenntag Biosector
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Vaccitech (University of Oxford spin-off)
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Emergent BioSolutions
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development
  • 11.13. Avanti Polar Lipids
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Benchmarking
    • 11.13.4. Recent Development
  • 11.14. Daiichi Sankyo
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Benchmarking
    • 11.14.4. Recent Development
  • 11.15. ImmunoScience
    • 11.15.1. Company Overview
    • 11.15.2. Financial Performance
    • 11.15.3. Product Benchmarking
    • 11.15.4. Recent Development

List of Tables:

  • Table 1 Global Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 2 Global Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 3 Global Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 4 Global Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 5 North America: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 6 North America: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 7 North America: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 8 North America: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 9 U.S.: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 10 U.S.: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 11 U.S.: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 12 U.S.: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 13 Canada: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 14 Canada: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 15 Canada: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 16 Canada: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 17 Europe: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 18 Europe: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 19 Europe: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 20 Europe: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 21 UK: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 22 UK: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 23 UK: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 24 UK: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 25 France: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 26 France: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 27 France: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 28 France: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 29 Germany: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 30 Germany: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 31 Germany: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 32 Germany: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 33 Italy: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 34 Italy: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 35 Italy: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 36 Italy: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 37 Spain: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 38 Spain: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 39 Spain: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 40 Spain: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 41 Netherlands: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 42 Netherlands: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 43 Netherlands: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 44 Netherlands: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 45 Russia: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 46 Russia: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 47 Russia: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 48 Russia: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 49 Rest of Europe: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 50 Rest of Europe: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 51 Rest of Europe: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 52 Rest of Europe: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 53 Asia Pacific: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 54 Asia Pacific: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 55 Asia Pacific: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 56 Asia Pacific: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 57 China: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 58 China: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 59 China: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 60 China: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 61 India: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 62 India: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 63 India: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 64 India: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 65 Malaysia: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 66 Malaysia: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 67 Malaysia: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 68 Malaysia: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 69 Japan: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 70 Japan: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 71 Japan: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 72 Japan: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 73 Indonesia: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 74 Indonesia: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 75 Indonesia: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 76 Indonesia: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 77 South Korea: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 78 South Korea: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 79 South Korea: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 80 South Korea: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 81 Australia: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 82 Australia: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 83 Australia: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 84 Australia: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 85 Rest of Asia Pacific: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 86 Rest of Asia Pacific: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 87 Rest of Asia Pacific: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 88 Rest of Asia Pacific: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 89 Middle East & Africa: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 90 Middle East & Africa: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 91 Middle East & Africa: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 92 Middle East & Africa: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 93 Saudi Arabia: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 94 Saudi Arabia: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 95 Saudi Arabia: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 96 Saudi Arabia: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 97 UAE: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 98 UAE: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 99 UAE: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 100 UAE: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 101 Israel: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 102 Israel: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 103 Israel: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 104 Israel: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 105 South Africa: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 106 South Africa: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 107 South Africa: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 108 South Africa: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 109 Rest of Middle East & Africa: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 110 Rest of Middle East & Africa: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 111 Rest of Middle East & Africa: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 112 Rest of Middle East & Africa: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 113 Latin America: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 114 Latin America: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 115 Latin America: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 116 Latin America: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 117 Mexico: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 118 Mexico: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 119 Mexico: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 120 Mexico: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 121 Brazil: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 122 Brazil: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 123 Brazil: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 124 Brazil: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 125 Argentina: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 126 Argentina: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 127 Argentina: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 128 Argentina: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
  • Table 129 Rest of Latin America: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  • Table 130 Rest of Latin America: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  • Table 131 Rest of Latin America: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  • Table 132 Rest of Latin America: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)

List of Figures:

  • Figure 1. Global Vaccine Adjuvants Market, 2020-2034 (USD Million)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Product Type
  • Figure 7. Global Vaccine Adjuvants Market, by Product Type, 2024 & 2034 (USD Million)
  • Figure 8. Market by Route of Administration
  • Figure 9. Global Vaccine Adjuvants Market, by Route of Administration, 2024 & 2034 (USD Million)
  • Figure 10. Market by Application
  • Figure 11. Global Vaccine Adjuvants Market, by Application, 2024 & 2034 (USD Million)
  • Figure 12. Market by Disease Type
  • Figure 13. Global Vaccine Adjuvants Market, by Disease Type, 2024 & 2034 (USD Million)